The Barbiturates Urine Drug Test quantitatively measures concentrations of key barbiturate drugs (e.g. phenobarbital, pentobarbital) in urine using mass spectrometry. This definitive analysis supports therapeutic monitoring, compliance tracking, and safety evaluation by providing precise levels rather than just presence/absence of barbiturates.

The Amphetamines Urine Drug Test quantitatively measures the concentration of amphetamine and methamphetamine in urine using advanced laboratory methods. This quantitative analysis provides precise levels to support clinical monitoring, treatment programs, or medical evaluation. It offers more information than a basic screen by showing how much of these compounds are present.

The Amphetamines Urine Drug Screen detects the presence of amphetamine and related compounds in urine above defined cutoff levels. This screening test provides an initial assessment of recent amphetamine use and is commonly applied in workplace, treatment, and clinical monitoring contexts. Results indicate detection at or above threshold limits but are not confirmed by additional testing.

The Barbiturates Urine Drug Screen detects the presence of barbiturate compounds in urine above established cutoff levels, using immunoassay methodology. This screening test is used in clinical, treatment, and monitoring settings to identify barbiturate use. A positive result indicates detection but does not include confirmatory testing, so results should be interpreted in context.

The Benzodiazepines Urine Drug Screen detects the presence of benzodiazepine compounds in urine above established cutoff levels using immunoassay techniques. This screening test identifies recent use of medications like diazepam, alprazolam, or lorazepam in clinical, treatment, or monitoring settings. Positive results indicate detection at threshold levels but are not confirmed by additional testing.

The Fentanyl Urine Drug Test quantitatively measures the concentration of fentanyl and its metabolites in urine using advanced analytical techniques. This precise testing approach gives detailed insight into levels of fentanyl exposure, supporting clinical evaluation, treatment monitoring, and substance use analysis beyond simple detection.

The Gabapentin Urine Drug Test quantitatively measures gabapentin levels in urine using advanced laboratory analysis. This precise assay provides actual concentration values (not just presence/absence), enabling clinicians to assess medication use, adherence, and exposure over time. It offers more detailed insight than a standard screen, helping differentiate between low-level exposure and therapeutic dosing.

The Meperidine Urine Drug Test quantitatively measures the concentration of meperidine and its metabolite(s) in urine using sensitive analytical methods. This precise test delivers numeric levels, enabling clinicians and monitoring programs to assess exposure, differentiate low versus significant use, and observe trends over time. It offers more insight than a simple detection screen.

The Oxycodone Urine Drug Screen detects the presence of oxycodone and related metabolites in urine above established cutoff levels using immunoassay screening. This test provides an initial indication of opioid exposure in clinical, treatment, or monitoring settings. A positive result signals detection beyond threshold, but confirmatory testing is not included in this version.

The Phencyclidine Urine Drug Screen detects PCP (phencyclidine) and its metabolites in urine using immunoassay screening above defined cutoff levels. This test offers an initial assessment of PCP exposure in clinical, monitoring, or treatment settings. Detection suggests recent use, but this version does not include confirmatory testing, so positive results should be interpreted with caution.

The Pregabalin Urine Drug Test quantitatively measures concentrations of pregabalin in urine using precise analytical methods, supporting clinical and treatment monitoring. This quantitative assay provides clear numeric levels rather than a simple positive/negative result, helping clinicians distinguish between low-level presence and meaningful dosing patterns, and assess compliance or exposure over time.

The Tapentadol Urine Drug Test quantitatively measures tapentadol and its metabolites in urine using advanced analytical techniques. This assay provides precise concentration values—rather than just presence—helping clinicians and monitoring programs gauge exposure levels, differentiate trace from significant use, and track individual usage patterns over time.

The Tramadol Urine Drug Test quantitatively measures tramadol and its metabolite concentrations in urine using precise analytical methods. This detailed test provides numeric values beyond simple detection, supporting clinicians and monitoring programs in assessing exposure levels, compliance, and usage trends over time.

The Fentanyl Urine Drug Screen detects the presence of fentanyl and its metabolites in urine above established cutoff levels using immunoassay screening methods. This test provides an initial assessment of opioid exposure, useful in clinical, monitoring, or treatment settings. A positive result indicates detection but does not include confirmatory testing.

The MDMA Urine Drug Screen detects the presence of MDMA (ecstasy) and related metabolites in urine above defined cutoff levels using immunoassay screening. This test offers an initial evaluation of recent MDMA use in clinical, treatment, or monitoring settings. A positive result indicates detection beyond threshold levels, but does not include confirmatory testing in this version.

The Opiates Urine Drug Screen detects the presence of opiate compounds (such as morphine, codeine, and related metabolites) in urine above predetermined cutoff levels using immunoassay methods. This screening test offers an initial detection of opiate use in clinical, monitoring, or treatment settings. Positive results indicate detection above threshold, but this version does not include confirmatory testing.

The Propoxyphene Urine Drug Screen detects propoxyphene and its metabolites (such as norpropoxyphene) in urine above defined cutoff levels using immunoassay screening. This test offers initial detection of propoxyphene exposure in clinical or monitoring settings. A positive result signals presence beyond threshold, but this version does not include confirmatory testing.

The Buprenorphine Urine Drug Screen detects the presence of buprenorphine and its metabolites in urine above established cutoff levels using immunoassay screening methods. This test is commonly used in treatment, clinical monitoring, and compliance settings to identify recent buprenorphine use. Positive results reflect detection, but do not include confirmatory testing.

The Mitragynine Urine Drug Test quantitatively measures mitragynine levels in urine, the principal alkaloid found in kratom, using sensitive analytical methods. This precise assay reports exact concentrations rather than just detection, giving clinicians and monitoring programs more insight into exposure, dosage trends, and user behavior over time in kratom use assessment.

The Methadone Urine Drug Screen detects the presence of methadone metabolites in urine above defined cutoff levels using immunoassay screening methods. This test provides a first-pass assessment of methadone use in clinical, monitoring, or treatment settings. Positive results indicate detection beyond threshold limits, but no confirmatory steps are included in this test version.

The Cocaine Urine Drug Test quantitatively measures the concentration of benzoylecgonine (the primary cocaine metabolite) in urine using high-precision analytical methods. This quantitative analysis provides more than detection—it reveals the level of cocaine exposure to support clinical monitoring, compliance evaluation, or detailed case review over time.

The Naltrexone Urine Drug Test quantitatively measures the concentration of naltrexone and its metabolites in urine using sensitive analytical techniques. This detailed assay provides numeric levels rather than just detection, supporting clinicians and monitoring programs in assessing adherence, dosage exposure, and treatment response. It helps distinguish low-level presence from medically relevant levels.

The Methadone Urine Drug Test quantitatively measures the concentration of methadone and its metabolites in urine using precise analytical techniques. This detailed assay provides numeric values, offering deeper insight into methadone exposure, compliance, or therapeutic monitoring. It gives clinicians more context than a basic screen by showing how much methadone is present.

The Eszopiclone Urine Drug Test quantitatively measures the concentration of eszopiclone (Lunesta®) and related metabolites in urine using sensitive analytical methods. This precise test supports clinical monitoring, adherence tracking, or medication evaluation by providing actual levels rather than simply detecting presence, offering more insight into drug exposure over time.

The Zolpidem Urine Drug Test quantitatively measures zolpidem levels in urine using precise laboratory techniques. This test provides exact concentration values rather than a simple presence or absence, helping clinicians assess exposure, monitor therapeutic use, and evaluate compliance or misuse. Quantitative results give a clearer picture of recent zolpidem intake patterns for accurate monitoring.